Navigation Links
Spherix Incorporated Announces Annual Shareholders Meeting Date
Date:9/23/2009

BETHESDA, Md., Sept. 23 /PRNewswire-FirstCall/ -- Spherix Incorporated (Nasdaq: SPEX), an innovator in biotechnology for diabetes therapy, and a provider of technical and regulatory consulting services to food, supplement, biotechnology and pharmaceutical companies, today announced that its Annual Meeting of Shareholders will be held on November 17, 2009, at 9:00 a.m. Eastern time, at the Bethesda Marriott Suites, 6711 Democracy Boulevard, Bethesda, Maryland 20817.

The items of business are:

  1. Election of seven Directors.
  2. Ratification of the appointment of the independent accountants.
  3. Proposal to authorize a reverse stock split of the Company's issued and outstanding common stock at a ratio to be designated by the Board of Directors within a range of 1:5 to 1:20.
  4. Transaction of other business that may properly come before the meeting.

In addition, the Company has fixed the close of business on September 18, 2009, as the Record Date for determination of shareholders entitled to notice of and to vote at the Annual Meeting and any adjournment thereof. Only shareholders of record on the date so fixed are entitled to vote. Proxy materials will be mailed to these shareholders on or about September 30, 2009.

About Spherix

Spherix Incorporated was launched in 1967 as a scientific research company, under the name Biospherics Research. The company now leverages its scientific and technical expertise and experience through its two subsidiaries -- Biospherics Incorporated and Spherix Consulting, Inc. Biospherics is currently running a Phase 3 clinical trial to study the use of Naturlose as a treatment for Type 2 diabetes. Its Spherix Consulting subsidiary provides sci
'/>"/>

SOURCE Spherix Incorporated
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related biology technology :

1. Spherix Incorporated Appoints Dr. Ram Nimmagudda As Director of New Business Development
2. Spherix Incorporated to Present at the Rodman & Renshaw 11th Annual Healthcare Conference
3. Spherix Reports Second Quarter 2009 Earnings
4. Spherix Announces Termination of Arla License Agreement
5. Spherix Announces Full-Scale Production of Pharmaceutical Tagatose
6. Spherix Regains Full NASDAQ Compliance
7. Spherix to Exhibit at the BIO 2009 International Convention
8. Spherix Recruiting New Independent Director to Regain NASDAQ Compliance
9. Spherix Incorporated Announces the Death of A. Paul Cox, Jr., Chairman of the Board
10. Spherix Announces 2008 Financial Results
11. Spherix Reports 3rd Quarter Earnings

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/30/2009)..., NOVATO, Calif., Nov. 30 /PRNewswire-FirstCall/...announced today that the Food and Drug Administrat...3,4-diaminopyridine (3,4-DAP), amifampridine phosp...n Myasthenic Syndrome (LEMS). 3,4-DAP has previou...Also, in October 2009, the Committee for Medicinal...
(Date:11/30/2009)... , BOSTON and COPENHAGEN, Nov. 30 /PRNewswire/...unced today that the Harvard Medical School ICCB-L...nized as a MicroRNA Screening Center of Excellence...l School, and associated hospitals and institution... and RNAi libraries. ,, MicroRNAs are a novel c...
(Date:11/30/2009)... , AMSTERDAM, Novem...ld,s,leading publisher of scientific, medical and ... major re-launch of Embase, its comprehensive biom...d records from more than 7,000,active, peer review...ey role in the advancement of new biomedical,and p...
(Date:11/27/2009)... , DURHAM, N.C., Nov. 27 C...l initiate water-soluble carbon nanotube-based can...water-soluble carbon nanotubes, which have functio...n with cancer drugs, was developed in partnership ...jugated carbon nanotubes serves as a drug delivery...
Breaking Biology Technology:FDA Grants Orphan Drug Designation for 3,4-DAP for LEMS 2FDA Grants Orphan Drug Designation for 3,4-DAP for LEMS 3FDA Grants Orphan Drug Designation for 3,4-DAP for LEMS 4Exiqon Recognizes Harvard Medical School Core Facility as MicroRNA Screening Center of Excellence 2Exiqon Recognizes Harvard Medical School Core Facility as MicroRNA Screening Center of Excellence 3Elsevier is Re-Launching "Embase" to be a Powerful Resource Providing Deep Insights and Answers to Biomedical Researchers 2Elsevier is Re-Launching "Embase" to be a Powerful Resource Providing Deep Insights and Answers to Biomedical Researchers 3North Carolina Based Cromoz Inc. Launches Carbon Nanotechnology for Target Drug Delivery System in Cancer Treatment in Hyderabad, India 2
...pt. 7 Human Genome,Sciences, Inc. (Nasdaq: HGSI ...r Stearns 20th Annual Healthcare Conference in New...://www.hgsi.com (Logo: http://www.newscom.com/c... Genome Sciences, senior management team will pres...er 11, 2007 at 4:00 pm,Eastern Time. Investors in...
...rolled in Second of Two Phase 3 Trials - Mo...al, - Trial Design Was Reviewed Under Special Pro... With The FDA, IRVINE, Calif., Sept. 7 Spec... announced today that it has,begun enrolling patie...rial,for EOquin, the Company,s drug candidate for ...
...Sept. 7 Varian Medical,Systems (NYSE: VAR ), wor...reating cancer, is demonstrating its full range of...speed and precision of radiotherapy at the,2007 Eu...ogy (ESTRO),meeting in Barcelona, Spain from Septe...s on show will be the Smart,Segmentation(TM) featu...
Other Biology Technology:Spectrum Pharmaceuticals Initiates Second Registrational Phase 3 Clinical Trial for EOquin(R) in Patients With Non-Invasive Bladder Cancer 2Spectrum Pharmaceuticals Initiates Second Registrational Phase 3 Clinical Trial for EOquin(R) in Patients With Non-Invasive Bladder Cancer 3Spectrum Pharmaceuticals Initiates Second Registrational Phase 3 Clinical Trial for EOquin(R) in Patients With Non-Invasive Bladder Cancer 4Varian Medical Systems Exhibits Latest Technologies and Products Designed to Improve Speed and Precision of Radiotherapy at ESTRO 2007 2Varian Medical Systems Exhibits Latest Technologies and Products Designed to Improve Speed and Precision of Radiotherapy at ESTRO 2007 3
(Date:11/24/2009)...-level action of a remarkable class of ring-shaped...with the Lawrence Berkeley National Laboratory (Be...allography beamline at the Advanced Light Source (...ene expression and replication, and are vital to t...fectious agents, such as the human papillomavirus,...
(Date:11/24/2009)...UGE Antarctica has long held secrets of the earth...ently, there has been very little information on t...s of ice for millions of years. Now, a team of res...ve been funded to the tune of $10 million dollars ... to the bottom of things literally. These scienti...
(Date:11/24/2009)...ase is available in Spanish . , The presenc...ls of inflammatory substances in the blood, hinder...n by a research project of the University of Navar...ist at the School of Pharmacy. , The project, en...elation to the control of body weight and inflamma...
Breaking Biology News(10 mins):Atomic-level snapshot catches protein motor in action 2Atomic-level snapshot catches protein motor in action 3Atomic-level snapshot catches protein motor in action 4LSU gets to the bottom of things -- in Antarctica 2It can be predicted the reaction obese patients will have to a diet 2Health Leaders Issue Recommendations to Improve Management of a Common Costly and Misunderstood Cardiovascular Disease 3A Atrial Fibrillation 57357 1Health Leaders Issue Recommendations to Improve Management of a Common Costly and Misunderstood Cardiovascular Disease 3A Atrial Fibrillation 57357 2Health Leaders Issue Recommendations to Improve Management of a Common Costly and Misunderstood Cardiovascular Disease 3A Atrial Fibrillation 57357 3Health Leaders Issue Recommendations to Improve Management of a Common Costly and Misunderstood Cardiovascular Disease 3A Atrial Fibrillation 57357 4Health Leaders Issue Recommendations to Improve Management of a Common Costly and Misunderstood Cardiovascular Disease 3A Atrial Fibrillation 57357 5Guayaki Delivers Powerful Rainforest Experience with Newest Yerba Mate Beverage Innovations 57354 1Guayaki Delivers Powerful Rainforest Experience with Newest Yerba Mate Beverage Innovations 57354 2Guayaki Delivers Powerful Rainforest Experience with Newest Yerba Mate Beverage Innovations 57354 3Critical Signal Technologies Acquires Link to Life to Grow Depth and Expertise in TeleHealth Personal Emergency Response and Medical Monitoring Syste 57351 1Critical Signal Technologies Acquires Link to Life to Grow Depth and Expertise in TeleHealth Personal Emergency Response and Medical Monitoring Syste 57351 2Critical Signal Technologies Acquires Link to Life to Grow Depth and Expertise in TeleHealth Personal Emergency Response and Medical Monitoring Syste 57351 3
... kidney tumors through percutaneous cryoablation s...tes for surgery. Their early findings showing sho...d patients are published in this month’s issue of ...ors is surgery, providing a high likelihood of a l...an option, and Mayo’s urologists and radiologists ...
... light, Stacie Grassano pulls out a tube. "This is... up to her face. Inside, a tree branch is speckled... says, handing it to Scott Costa. , Costa brings t... boyish grin, "this is a fungus success story." ...is growing at the back of their refrigerator. But ...
... boosted the number of marine turtles visiting UK ...ts. , New research by the University of Exeter an...week in Marine Biology (3 May 2007), analyses 100 ...of loggerhead and Kemp’s ridley turtles in UK and ...ch team believes this is most likely the result of...
Other Biology News:Cryoablation -- A new treatment option for some kidney tumor patients 2Cryoablation -- A new treatment option for some kidney tumor patients 3Immunization rates hit record high in poor countries 2Immunization rates hit record high in poor countries 3US conservation efforts bring more marine turtles to UK 2
BD Falcon cultivation flask from BD Biosciences - Discovery Labware
Mini Incubation Trays, 100 from Bio-Rad
...ion Kit specifically removes 20 of the most abunda...ion for further proteomics analysis. This depletio...ome whether you use one- or two-dimensional electr...hy or go straight to mass spectrometry. This is ba...
...stry's first siRNA sequence design software in 200...consistent with new experimental strategies and pu...th the introduction of our new, enhanced, and expa...offer the most significant advancement in RNAi res...
Biology Products: